Separation of achiral anti-diabetic drugs using sub/supercritical fluid chromatography with a polysaccharide stationary phase: Thermodynamic considerations and molecular docking study
Abstract
A simple, fast and environmental friendly supercritical fluid chromatography-photodiode array (SFC-PDA) method was developed for the simultaneous determination of metformin and three sodium-glucose co-transporter 2 (SGLT-2) inhibitors (canagliflozin, dapagliflozin and empagliflozin). The impact of different stationary phases, co-solvents, column temperature and outlet pressure was extensively evaluated for selective separation and quantitation of the drugs. Amongst several achiral and chiral stationary phases tested, the best results were obtained on amylose based Chiralpak IG column using CO2 and 0.1 % diethylamine in methanol and isopropanol 50:50 (v/v) in 60:40 ratios as the mobile phase. The separation efficiency was mainly dependent on the nature of stationary phase and the mobile phase composition. The limit of detection (LOD) and quantitation (LOQ) of the method were 0.155 and 0.469, 0.062 and 0.187, 0.015 and 0.045, 0.028 and 0.084 μg/mL for metformin, canagliflozin, dapagliflozin and empagliflozin, respectively. The chromatographic resolution between metformin-canagliflozin, metformin-dapagliflozin and metformin-empagliflozin pairs was 6.87, 3.44 and 6.47, respectively. The intra-batch and inter-batch precision of the method was ≤1.64 % while the accuracy was in the range of 96.2-103.3 %. The method was used to analyze metformin and SGLT-2 inhibitors in their binary fixed-dose formulations with acceptable accuracy (recovery) and precision. To support the…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.